Non-Small Cell Lung Cancer Biomarkers and Genomic Testing

KRAS mutations were once considered “undruggable,” but that’s quickly changing. Recent advances in pancreatic cancer research are carrying over to lung cancer. Daraxonrasib, a targeted therapy designed to block multiple KRAS mutations, recently became an important new treatment option for people with advanced pancreatic cancer. In a clinical trial, people treated with daraxonrasib lived a […]

Unlock personalized care by decoding your NSCLC pathology report. Learn how subtypes, EGFR, and PD-L1 levels guide your lung cancer treatment and survival path.

Understand why your specific EGFR mutation is the key to effective lung cancer treatment. Learn about targeted therapies, inhibitors, and improving survival.

For people living with KRAS G12D-mutated non-small cell lung cancer (NSCLC), treatment options after standard therapies stop working have been very limited. New research presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting offers encouraging news. An investigational targeted therapy called zoldonrasib showed promising results and manageable side effects in patients with […]

NCCN Guidelines® for ROS1 fusion–positive non–small cell lung cancer (NSCLC) have evolved in important ways, and for patients, these changes can have a real impact on outcomes and quality of life. We asked Georgetown University’s Dr. Stephen Liu to explain what these updates mean for your care and the topics you should be bringing to […]

ALK-positive (ALK+) lung cancer is a type of lung cancer driven by a genetic change called an ALK fusion. Georgetown University’s Dr. Stephen Liu explains, “ALK+ refers to a cancer that has an ALK fusion or a chromosomal rearrangement within the ALK gene.” This change acts like an “on switch,” fueling cancer growth. ALK fusions […]

With some new changes to the NCCN Guidelines® for Non-Small Cell Lung Cancer (NSCLC) that affect patients with a ROS1 fusion or an ALK mutation, you may be wondering if these updates affect you. We asked Georgetown University’s Dr. Stephen V. Liu to break down the latest guidance for these subgroups. https://vimeo.com/1105210909/098bfadf14?ts=0&share=copy Transcript The transcript […]

Is it possible for your non-small cell lung cancer to be ALK-positive and have a ROS1 fusion? Georgetown University’s Lombardi Comprehensive Cancer Center’s Dr. Stephen V. Liu explains how this could happen with on-target resistance and the potential treatment paths your care team may recommend in this scenario in this Precision Minute recap. https://vimeo.com/1096912989/15b430dbe4?share=copy Transcript […]

Testing for ROS1 fusions in non-small cell lung cancer (NSCLC) is essential for identifying patients who may benefit from highly effective targeted therapies. We asked thoracic oncologist Dr. Stephen V. Liu to explain ROS1 fusions, how ROS1 inhibitors work, and what you can expect if you’re on these newer treatments in this “Precision Minute” recap. […]

What does it mean to have ALK-positive lung cancer, and why does it matter for your treatment? Georgetown University’s Dr. Stephen V. Liu offers the latest advances in ALK inhibitors and how these drugs are transforming care for many non-small cell lung cancer patients. Learn how these therapies work, how long they remain effective, and […]

The role of biomarker testing in personalized lung cancer treatment Non-small cell lung cancer (NSCLC) is a complex diagnosis with many different subsets that can be difficult to navigate. In our webinar with Mass General Cancer Center’s Dr. Jessica Lin, we break down some of the mutations that occur in NSCLC and how biomarker testing […]

Biomarker testing is a critical component for identifying genetic mutations and resistance mechanisms for patients with non-small cell lung cancer (NSCLC). We had the honor of hosting Mass General Cancer Center’s Dr. Jessica Lin for a webinar on how advancements in biomarker testing are transforming the landscape of lung cancer care and treatments. You can […]